<![CDATA[Biotek-snakken — August 2024]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/topic/401446/biotek-snakken-august-2024RSS for NodeSat, 06 Jun 2026 04:40:58 GMTThu, 01 Aug 2024 02:07:14 GMT60<![CDATA[Reply to Biotek-snakken — August 2024 on Sat, 31 Aug 2024 06:56:56 GMT]]>IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA https://proinvestor.com/investornyt/1207657/io-biotechs-phase-3-trial-data-fails-to-show-superiority-in-orr-for-io102-io103-with-keytruda

]]>https://dev.proinvestor.com/forum/post/8067663https://dev.proinvestor.com/forum/post/8067663Sat, 31 Aug 2024 06:56:56 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Sat, 31 Aug 2024 04:51:02 GMT]]>Infant Bacterial Therapeutics fase III-studie

Link til uddybende debat:

Just a moment...

favicon

(proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/8067661https://dev.proinvestor.com/forum/post/8067661Sat, 31 Aug 2024 04:51:02 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Sat, 31 Aug 2024 04:22:04 GMT]]>IBT’s phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality (August 30, 2024)

Link Preview Image
IBT | IBT’s phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality

favicon

(ibtherapeutics.com)

(nu med link)

]]>https://dev.proinvestor.com/forum/post/8067660https://dev.proinvestor.com/forum/post/8067660Sat, 31 Aug 2024 04:22:04 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Sat, 31 Aug 2024 03:46:40 GMT]]>IBT misser first endpoint. Men viser significant effekt i dødelighed og søger om registrering hos FDA.

]]>https://dev.proinvestor.com/forum/post/8067659https://dev.proinvestor.com/forum/post/8067659Sat, 31 Aug 2024 03:46:40 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Sat, 31 Aug 2024 03:34:24 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067665https://dev.proinvestor.com/forum/post/8067665Sat, 31 Aug 2024 03:34:24 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 06:14:33 GMT]]>Xbrane Biopharma Q2 2024: A fight against the clock

Just a moment...

favicon

(www.redeye.se)

]]>https://dev.proinvestor.com/forum/post/8067657https://dev.proinvestor.com/forum/post/8067657Fri, 30 Aug 2024 06:14:33 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 06:08:35 GMT]]>Nästa steg för Orviglance blir nu att arbeta med att ta fram en marknadsansökan till regulatoriska myndigheter, vilket bolaget bedömer kommer kunna skickas in under mitten av 2025. Detta skulle implicera ett potentiellt marknadsgodkännande för Orviglance under 2026

]]>https://dev.proinvestor.com/forum/post/8067658https://dev.proinvestor.com/forum/post/8067658Fri, 30 Aug 2024 06:08:35 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 06:08:26 GMT]]>Höjdpunkter från presentationen

Bolagets VD Magnus Corfitzen deltog igår på Carnegies Småbolagsdag 2024. Presentationen innehöll inga större överraskningar och sammanfattade utvecklingsläget i bolagets huvudprojekt Orviglance och Oncoral. Vi förväntar oss den fullständiga datautläsningen av SPARKLE-studien under Q4(24).

]]>https://dev.proinvestor.com/forum/post/8067656https://dev.proinvestor.com/forum/post/8067656Fri, 30 Aug 2024 06:08:26 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 06:07:44 GMT]]>Penser Access & Future by Carnegie: Ascelia Pharma: Höjdpunkter från Carnegies Småbolagsdag 2024

Ascelia Pharma presentation - Carnegie småbolagsdag:

]]>https://dev.proinvestor.com/forum/post/8067664https://dev.proinvestor.com/forum/post/8067664Fri, 30 Aug 2024 06:07:44 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 04:54:36 GMT]]>Er gået med mht. Ascelia Pharma / pengene er allerede trukket hos SAXO 🙂

]]>https://dev.proinvestor.com/forum/post/8067654https://dev.proinvestor.com/forum/post/8067654Fri, 30 Aug 2024 04:54:36 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 04:54:26 GMT]]>God morgen 🙂

]]>https://dev.proinvestor.com/forum/post/8067651https://dev.proinvestor.com/forum/post/8067651Fri, 30 Aug 2024 04:54:26 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 03:52:33 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8067662https://dev.proinvestor.com/forum/post/8067662Fri, 30 Aug 2024 03:52:33 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Fri, 30 Aug 2024 01:31:28 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067648https://dev.proinvestor.com/forum/post/8067648Fri, 30 Aug 2024 01:31:28 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Thu, 29 Aug 2024 03:55:30 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8067649https://dev.proinvestor.com/forum/post/8067649Thu, 29 Aug 2024 03:55:30 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Thu, 29 Aug 2024 02:32:25 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067647https://dev.proinvestor.com/forum/post/8067647Thu, 29 Aug 2024 02:32:25 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Wed, 28 Aug 2024 05:03:25 GMT]]>This spring, the regulatory work began to prepare IBT's drug application for IBP-9414. The work has intensified, and more sections are ready. As soon as we have received results from “The Connection Study” IBT intends to contact the FDA and discuss how they want us to submit our data with the objective of reaching the market as soon as possible

]]>https://dev.proinvestor.com/forum/post/8067655https://dev.proinvestor.com/forum/post/8067655Wed, 28 Aug 2024 05:03:25 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Wed, 28 Aug 2024 05:01:49 GMT]]>IBT has announced the crucial results from the global clinical phase 3 study “The Connection Study” for our drug project IBP-9414 are expected in Q3 2024.

]]>https://dev.proinvestor.com/forum/post/8067650https://dev.proinvestor.com/forum/post/8067650Wed, 28 Aug 2024 05:01:49 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Wed, 28 Aug 2024 04:58:39 GMT]]>Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024 https://storage.mfn.se/e4463f81-0644-4c84-87fa-25f773e47ef8/ibt-q2-2024-eng.pdf

]]>https://dev.proinvestor.com/forum/post/8067645https://dev.proinvestor.com/forum/post/8067645Wed, 28 Aug 2024 04:58:39 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Wed, 28 Aug 2024 03:24:30 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8067652https://dev.proinvestor.com/forum/post/8067652Wed, 28 Aug 2024 03:24:30 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Wed, 28 Aug 2024 01:37:06 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067653https://dev.proinvestor.com/forum/post/8067653Wed, 28 Aug 2024 01:37:06 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Tue, 27 Aug 2024 03:20:23 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8067644https://dev.proinvestor.com/forum/post/8067644Tue, 27 Aug 2024 03:20:23 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Tue, 27 Aug 2024 02:31:41 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067643https://dev.proinvestor.com/forum/post/8067643Tue, 27 Aug 2024 02:31:41 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Tue, 27 Aug 2024 02:31:29 GMT]]>Godm
orgen...

]]>https://dev.proinvestor.com/forum/post/8067642https://dev.proinvestor.com/forum/post/8067642Tue, 27 Aug 2024 02:31:29 GMT<![CDATA[Reply to Biotek-snakken — August 2024 on Mon, 26 Aug 2024 02:21:57 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8067641https://dev.proinvestor.com/forum/post/8067641Mon, 26 Aug 2024 02:21:57 GMT